Search
Publications Icon

Publications

Why do publications about LTFU Study results refer to the Childhood Cancer Survivor Study (CCSS)?

Long-Term Follow-Up Study (LTFU) is the name we use when communicating about the study with participants, while Childhood Cancer Survivor Study (CCSS) is the scientific name used by researchers and the medical community. “Long-Term Follow-Up Study” emphasizes what the study is about without disclosing that some participants may be survivors of childhood cancer, thus protecting their personal health information.

You may hear about the Childhood Cancer Survivor Study or CCSS when important new findings are reported in the news. We want you to take pride in the attention the study receives, because your dedication contributes to every advance we make in protecting the health of survivors.

We're sorry, it looks like there has been an error. Please try again soon.

  • Experiences of adult survivors of childhood cancer in a randomized cardiovascular health promotion trial: a qualitative report from the Childhood Cancer Survivor Study

    2023

    Citation: 18(5):1665-1673

    Author(s): Cai CR, Cornelius S, Demedis J, Hagen AM, Abbey-Lambertz M, Armstrong GT, Oeffinger KC, Syrjala KL, Taylor SL, Yi JC, Chow EJ

    Journal: J Cancer Surviv

  • Financial hardship in adult survivors of childhood cancer in the era after implementation of the Affordable Care Act: a report from the Childhood Cancer Survivor Study

    2023

    Citation: 41(5):1000-1010

    Author(s): Nathan PC, Huang I, Chen Y, Henderson TO, Park ER, Kirchhoff AC, Robison LL, Krull K, Leisenring W, Armstrong GT, Conti RM, Yasui Y, Yabroff KR

    Journal: J Clin Oncol

  • Financial hardship in childhood cancer survivors treated with hematopoietic cell transplantation: a report from the Childhood Cancer Survivor Study

    2023

    Citation: 29(11):705.e1-705.e9

    Author(s): Buchbinder D, Bhatt NS, Wang H, Yasui Y, Armenian S, Bhatia S. Chow EJ, Huang I, Kirchoff AC, Leisenring W, Park ER, Yabroff KR, Armstrong GT, Nathan PC, Khera N

    Journal: Transplant Cell Ther

  • Gene-level analysis of anthracycline-induced cardiomyopathy in cancer survivors: a report from COG-ALTE03N1, BMTSS and CCSS

    2023

    Citation: 5(6):807-818

    Author(s): Sharafeldin N, Zhou L, Singh P, Crossman DK, Wang X, Hageman L, Landier W, Blanco JG, Burridge PW, Sapkota Y, Yasui Y, Armstrong GT, Robison LL, Hudson MM, Oeffinger KC, Chow EJ, Armenian SH, Weisdorf DJ, Bhatia S

    Journal: JACC CardioOncol

  • Genome-wide association study identifies ROBO2 as a novel susceptibility gene for anthracycline-related cardiomyopathy in childhood cancer survivors

    2023

    Citation: 41(9):1758-1769

    Author(s): Wang X, Singh P, Zhou L, Sharafeldin N, Landier W, Hageman L, Burridge P, Yasui Y, Sapkota Y, Blanco JG, Oeffinger K, Hudson MM, Chow EJ, Armenian SH, Neglia JP, Ritchey AK, Hawkins DS, Ginsberg JP, Robison LL, Armstrong GT, Bhatia S

    Journal: J Clin Oncol

Related Information